| Latent multivariate log-gamma models for high-dimensional multitype responses with application to daily fine particulate matter and mortality counts Z Xu, JR Bradley, D Sinha The Annals of Applied Statistics 17 (2), 1175-1198, 2023 | 12* | 2023 |
| Utilization of treatment effect on a surrogate endpoint for planning a study to evaluate treatment effect on a final endpoint H Quan, Z Xu, J Luo, G Paux, M Cho, X Chen Pharmaceutical Statistics 22 (4), 633-649, 2023 | 3 | 2023 |
| Historical control data borrowing for noninferiority assessment H Quan, Z Xu, M Cho, Y Dong, N Jia Statistics in Biopharmaceutical Research 14 (4), 463-472, 2022 | 3 | 2022 |
| A MCP‐Mod approach to designing and analyzing survival trials with potential non‐proportional hazards X Luo, Y Sun, Z Xu Pharmaceutical Statistics 21 (6), 1294-1308, 2022 | 2 | 2022 |
| Bivariate Bayesian hypothesis testing with missing data in components Z Xu, H Quan Pharmaceutical Statistics 21 (2), 395-417, 2022 | 2 | 2022 |
| Joint analysis of recurrence and termination: A Bayesian latent class approach Z Xu, D Sinha, JR Bradley Statistical methods in medical research 30 (2), 508-522, 2021 | 2 | 2021 |
| MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results (P6-3.012) D Reich, A Traboulsee, S Syed, Z Xu, T Turner, D Arnold Neurology 100 (17_supplement_2), 1828, 2023 | 1 | 2023 |
| MRI, Efficacy, and Safety of Tolebrutinib in Participants with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-Term Safety (LTS) Study RJ Fox, J Oh, DL Arnold, S Syed, Z Xu, TJ Turner, A Traboulsee, ... 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers, 2023 | | 2023 |
| MRI, Efficacy, and Safety of Tolebrutinib in Patients with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-term Safety (LTS) Study (P6-3.017) R Fox, J Oh, D Arnold, S Syed, Z Xu, T Turner, A Traboulsee, D Reich Neurology 100 (17_supplement_2), 1827, 2023 | | 2023 |
| Sécurité d’emploi et efficacité clinique du tolébrutinib dans l’étude d’extension à long terme chez des patients atteints de SEP récurrente: résultats à 2 ans J Oh, S Syed, L Orogun, Z Xu, TJ Turner, RJ Fox Revue Neurologique 179, S163, 2023 | | 2023 |
| Integration of Efficacy Biomarkers Together with Toxicity Endpoints in Immune-Oncology Dose Finding Studies Y Zhang, Z Xu, H Quan, J Lin arXiv preprint arXiv:2302.04777, 2023 | | 2023 |
| MRI outcomes from the long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results DS Reich, A Traboulsee, S Syed, Z Xu, TJ Turner, DL Arnold MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 334-335, 2022 | | 2022 |
| Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results J Oh, S Syed, L Orogun, Z Xu, TJ Turner, RJ Fox MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 342-343, 2022 | | 2022 |
| Survival Analysis Using Bayesian Joint Models Z Xu The Florida State University, 2019 | | 2019 |
debajyoti sinhaFLORIDA STATE UNIVERSITY在 stat.fsu.edu 的电子邮件经过验证
debajyoti sinhaFLORIDA STATE UNIVERSITY在 stat.fsu.edu 的电子邮件经过验证
Hui QuanMerck Sanofi在 sanofi.com 的电子邮件经过验证
Gautier PauxSanofi在 paux.fr 的电子邮件经过验证